A detailed history of Parallel Advisors, LLC transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Parallel Advisors, LLC holds 124 shares of BCRX stock, worth $871. This represents 0.0% of its overall portfolio holdings.

Number of Shares
124
Previous 93 33.33%
Holding current value
$871
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$6.41 - $8.69 $198 - $269
31 Added 33.33%
124 $0
Q2 2024

Aug 08, 2024

BUY
$4.13 - $6.79 $384 - $631
93 New
93 $0
Q3 2023

May 20, 2024

BUY
$6.71 - $7.92 $87 - $102
13 Added 48.15%
40 $0
Q3 2023

Nov 13, 2023

BUY
$6.71 - $7.92 $87 - $102
13 Added 48.15%
40 $0
Q2 2023

May 20, 2024

BUY
$6.96 - $8.81 $187 - $237
27 New
27 $0
Q2 2023

Aug 04, 2023

BUY
$6.96 - $8.81 $187 - $237
27 New
27 $0
Q3 2022

Nov 10, 2022

BUY
$10.79 - $14.81 $107 - $148
10 New
10 $0
Q2 2022

Aug 01, 2022

SELL
$7.89 - $17.88 $71 - $160
-9 Closed
0 $0
Q1 2022

Apr 28, 2022

BUY
$11.56 - $19.76 $104 - $177
9 New
9 $0
Q4 2021

Jan 20, 2022

SELL
$11.18 - $15.46 $201 - $278
-18 Closed
0 $0
Q3 2021

Nov 02, 2021

BUY
$14.21 - $17.65 $255 - $317
18 New
18 $0

Others Institutions Holding BCRX

About BIOCRYST PHARMACEUTICALS INC


  • Ticker BCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,944,992
  • Market Cap $1.31B
  • Description
  • BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...
More about BCRX
Track This Portfolio

Track Parallel Advisors, LLC Portfolio

Follow Parallel Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Parallel Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Parallel Advisors, LLC with notifications on news.